PURPOSE: The prognosis of metastatic prostate cancer significantly differs among individuals. While various clinical and biochemical prognostic factors for survival have been suggested, the progression and response to treatment of those patients may also be defined by host genetic factors. In this study, we evaluated genetic polymorphisms as prognostic predictors of metastatic prostate cancer. PATIENTS AND METHODS: One hundred eleven prostate cancer patients with bone metastasis at the diagnosis were enrolled in this study. Thirteen genetic polymorphisms were genotyped using polymerase chain reaction-restriction fragment length polymorphism or an automated sequencer with a genotyping software. RESULTS: Among the polymorphisms, the long allele (over 18 [CA] repeats) of insulin-like growth factor-I (IGF-I) and the long allele (over seven [TTTA] repeats) of cytochrome P450 (CYP) 19 were significantly associated with a worse cancer-specific survival (P = .016 and .025 by logrank test, respectively). The presence of the long allele of either the IGF-I or CYP19 polymorphisms was an independent risk factor for death (P = .019 or .026, respectively). Furthermore, the presence of the long allele of both the IGF-I and CYP19 polymorphisms was a stronger predictor for survival (P = .001). CONCLUSION: The prognosis of metastatic prostate cancer patients is suggested to be influenced by intrinsic genetic factors. The IGF-I (CA) repeat and CYP19 (TTTA) repeat polymorphisms may be novel predictors in prostate cancer patients with bone metastasis at the diagnosis.
PURPOSE: The prognosis of metastatic prostate cancer significantly differs among individuals. While various clinical and biochemical prognostic factors for survival have been suggested, the progression and response to treatment of those patients may also be defined by host genetic factors. In this study, we evaluated genetic polymorphisms as prognostic predictors of metastatic prostate cancer. PATIENTS AND METHODS: One hundred eleven prostate cancerpatients with bone metastasis at the diagnosis were enrolled in this study. Thirteen genetic polymorphisms were genotyped using polymerase chain reaction-restriction fragment length polymorphism or an automated sequencer with a genotyping software. RESULTS: Among the polymorphisms, the long allele (over 18 [CA] repeats) of insulin-like growth factor-I (IGF-I) and the long allele (over seven [TTTA] repeats) of cytochrome P450 (CYP) 19 were significantly associated with a worse cancer-specific survival (P = .016 and .025 by logrank test, respectively). The presence of the long allele of either the IGF-I or CYP19 polymorphisms was an independent risk factor for death (P = .019 or .026, respectively). Furthermore, the presence of the long allele of both the IGF-I and CYP19 polymorphisms was a stronger predictor for survival (P = .001). CONCLUSION: The prognosis of metastatic prostate cancerpatients is suggested to be influenced by intrinsic genetic factors. The IGF-I (CA) repeat and CYP19 (TTTA) repeat polymorphisms may be novel predictors in prostate cancerpatients with bone metastasis at the diagnosis.
Authors: Ahmad Hammoud; Douglas T Carrell; A Wayne Meikle; Yuanpei Xin; Steven C Hunt; Ted D Adams; Mark Gibson Journal: Fertil Steril Date: 2009-12-11 Impact factor: 7.329
Authors: Cathrine Hoyo; Janet Grubber; Wendy Demark-Wahnefried; Jeffrey R Marks; Stephen J Freedland; Amy S Jeffreys; Steven C Grambow; Robert M Wenham; Philip J Walther; Joellen M Schildkraut Journal: J Natl Med Assoc Date: 2007-07 Impact factor: 1.798
Authors: Akinobu Hamada; Tristan Sissung; Douglas K Price; Romano Danesi; Cindy H Chau; Nima Sharifi; David Venzon; Kenji Maeda; Keisuke Nagao; Alex Sparreboom; Hiroaki Mitsuya; William L Dahut; William D Figg Journal: Clin Cancer Res Date: 2008-06-01 Impact factor: 12.531
Authors: Michael Rauchenwald; Maria De Santis; Eleonore Fink; Wolfgang Höltl; Gero Kramer; Isabella-Carolina Marei; Hans-Jörg Neumann; Andreas Reissigl; Nikolaus Schmeller; Walter Stackl; Alfred Hobisch; Michael Krainer Journal: Wien Klin Wochenschr Date: 2008 Impact factor: 1.704
Authors: Axel Muendlein; Alois H Lang; Simone Geller-Rhomberg; Thomas Winder; Klaus Gasser; Heinz Drexel; Thomas Decker; Elisabeth Mueller-Holzner; Martina Chamson; Christian Marth; Michael Hubalek Journal: J Cancer Res Clin Oncol Date: 2012-11-23 Impact factor: 4.553